Abstract
Keloids are induced by skin injuries such as surgeries, skin piercings, burns, and trauma. The intra-lesional injection of 5-fluorouracil (5-FU) is a promising therapy to treat keloid. However, local 5-FU injections have caused several side effects such as pain at administration and hyperpigmentation. This study suggests a safer and more effective 5-FU delivery system. We used microneedles to treat keloid because this method has the feasibility of self-administration without pain. In this study, 5-FU-loaded carboxymethyl chitosan (CMC) nanoparticles were prepared and characterized by various analytical methods and then coated on stainless solid microneedles. The blank CMC nanoparticles caused an increase in cell viability on human normal fibroblasts to 150%. In particular, the 5-FU-loaded CMC nanoparticles showed a significant inhibitory effect on the human keloid fibroblast to 16%. The intercellular uptake of the 5-FU-loaded CMC nanoparticles was observed on both human normal and keloid fibroblasts by using a confocal microscope. In addition, it was found that the nanoparticles showed an inhibition of TGF-β1 by ELISA. For topical drug delivery, it was confirmed that the nanoparticles coated onto the microneedles were dissolved and diffused at the administration site in the porcine dorsal skin model. According to these results, the suggested microneedle-mediated drug delivery system not only inhibits the human keloid fibroblasts by delivering drugs effectively into the keloids but also has the feasibility to self-administer without pain. Therefore, this new system including 5-FU-loaded CMC nanoparticles and microneedles has the potential to treat keloid scars.
Similar content being viewed by others
References
Mari W, Alsabri SG, Tabal N, Younes S, Sherif A, Simman R. Novel insights on understanding of keloid scar: article review. J Am Coll Clin Wound Spec. 2015;7(1–3):1–7.
Hochman B, Isoldi FC, Furtado F, Ferreira LM. New approach to the understanding of keloid: psychoneuroimmune–endocrine aspects. Clin Cosmet Investig Dermatol. 2015;8:67.
Ehrlich HP, Desmoulière A, Diegelmann RF, Cohen IK, Compton CC, Garner WL, et al. Morphological and immunochemical differences between keloid and hypertrophic scar. Am J Pathol. 1994;145(1):105–13.
Yeo DC, Chew SW, Xu C. Polymeric biomaterials for management of pathological scarring. ACS Appl Polym Mater. 2019;1(4):612–24.
Mourya V, Inamdar NN, Tiwari A. Carboxymethyl chitosan and its applications. Adv Mater Lett. 2010;1(1):11–33.
Chen X-G, Wang Z, Liu W-S, Park H-J. The effect of carboxymethyl-chitosan on proliferation and collagen secretion of normal and keloid skin fibroblasts. Biomaterials. 2002;23(23):4609–14.
Feng C, Chen X, Zhang J, Sun G, Cheng X, Wang Z, et al. The effect of carboxymethyl-chitosan nanoparticles on proliferation of keloid fibroblast. Front Chem China. 2011;6(1):31–7.
Shah VV, Aldahan AS, Mlacker S, Alsaidan M, Samarkandy S, Nouri K. 5-fluorouracil in the treatment of keloids and hypertrophic scars: a comprehensive review of the literature. Dermatol Ther. 2016;6(2):169–83.
Shivaswamy KN, et al. Clinical efficacy of low dose intralesional 5-fluorouracil (5-FU) in the treatment of keloids. JEMDS. 2015;4(97):16229–32.
Gupta S, Kalra A. Efficacy and safety of intralesional 5-fluorouracil in the treatment of keloids. Dermatology. 2002;204(2):130–2.
Kim Y-C, Quan F-S, Yoo D-G, Compans RW, Kang S-M, Prausnitz MR. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis. 2010;201(2):190–8.
Yeo DC, Balmayor ER, Schantz J-T, Xu C. Microneedle physical contact as a therapeutic for abnormal scars. Eur J Med Res. 2017;22(1):28.
Snima KS, Jayakumar R, Unnikrishnan AG, Nair SV, Lakshmanan VK. O-Carboxymethyl chitosan nanoparticles for metformin delivery to pancreatic cancer cells. Carbohydr Polym. 2012;89(3):1003–7.
Anitha A, Divya Rani VV, Krishna R, Sreeja V, Selvamurugan N, Nair SV, et al. Synthesis, characterization, cytotoxicity and antibacterial studies of chitosan, O-carboxymethyl and N, O-carboxymethyl chitosan nanoparticles. Carbohydr Polym. 2009;78(4):672–7.
Maya S, Kumar LG, Sarmento B, Sanoj Rejinold N, Menon D, Nair SV, et al. Cetuximab conjugated O-carboxymethyl chitosan nanoparticles for targeting EGFR overexpressing cancer cells. Carbohydr Polym. 2013;93(2):661–9.
Shin J-H, Noh J-Y, Kim K-H, Park J-K, Lee J-H, Jeong SD, et al. Effect of zymosan and poly (I: C) adjuvants on responses to microneedle immunization coated with whole inactivated influenza vaccine. J Control Release. 2017;265:83–92.
Kim H-G, Gater DL, Kim Y-C. Development of transdermal vitamin D3 (VD3) delivery system using combinations of PLGA nanoparticles and microneedles. Drug Deliv Transl Res. 2018;8(1):281–90.
Kim Y-C, Quan F-S, Yoo D-G, Compans RW, Kang S-M, Prausnitz MR. Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine. 2009;27(49):6932–8.
Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J Control Release. 2007;117(2):227–37.
Ogiso T, Yamaguchi T, Iwaki M, Tanino T, Miyake Y. Effect of positively and negatively charged liposomes on skin permeation of drugs. J Drug Target. 2001;9(1):49–59.
Rokhade A. P., et al. semi-interpenetrating polymer network microspheres of gelatin and sodium carboxymethyl cellulose for controlled release of ketorolac tromethamine. Carbohydr Polym. 2006;65(3):243–52.
Ji J, Hao S, Dong J, Wu D, Yang B, Xu Y. Preparation, evaluation, and in vitro release study of O-carboxymethyl chitosan nanoparticles loaded with gentamicin and salicylic acid. J Appl Polym Sci. 2012;123(3):1684–9.
Eskandar NG, et al. Nanoparticle coated submicron emulsions: sustained in-vitro release and improved dermal delivery of all-trans-retinol. Pharm Res. 2009;26(7):1764–75.
Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–8.
Zhong Z, Li P, Xing R, Liu S. Antimicrobial activity of hydroxylbenzenesulfonailides derivatives of chitosan, chitosan sulfates and carboxymethyl chitosan. Int J Biol Macromol. 2009;45(2):163–8.
Farag R, Mohamed R. Synthesis and characterization of carboxymethyl chitosan nanogels for swelling studies and antimicrobial activity. Molecules. 2012;18(1):190–203.
Hietanen KE, et al. Treatment of keloid scars with intralesional triamcinolone and 5-fluorouracil injections–a randomized controlled trial. J Plast Reconstr Aesthet Surg. 2019;72(1):4–11.
Apikian M, Goodman G. Intralesional 5-fluorouracil in the treatment of keloid scars. Australas J Dermatol. 2004;45(2):140–3.
Goldan O, Weissman O, Regev E, Haik J, Winkler E. Treatment of postdermabrasion facial hypertrophic and keloid scars with intralesional 5-fluorouracil injections. Aesthet Plast Surg. 2008;32(2):389–92.
Chin GS, Liu W, Peled Z, Lee TY, Steinbrech DS, Hsu M, et al. Differential expression of transforming growth factor-beta receptors I and II and activation of Smad 3 in keloid fibroblasts. Plast Reconstr Surg. 2001;108(2):423–9.
Chin D, Boyle GM, Parsons PG, Coman WB. What is transforming growth factor-beta (TGF-β)? Br J Plast Surg. 2004;57(3):215–21.
Robles DT, Moore E, Draznin M, Berg D. Keloids: pathophysiology and management. Dermatol Online J. 2007;13(3):9.
Wendling J, Marchand A, Mauviel A, Verrecchia F. 5-Fluorouracil blocks transforming growth factor-β–induced α2 type I collagen gene (COL1A2) expression in human fibroblasts via c-Jun NH2-terminal kinase/activator protein-1 activation. Mol Pharmacol. 2003;64(3):707–13.
Huang L, Cai YJ, Lung I, Leung BC, Burd A. A study of the combination of triamcinolone and 5-fluorouracil in modulating keloid fibroblasts in vitro. J Plast Reconstr Aesthet Surg. 2013;66(9):e251–e9.
Lv C, Dai H, Xing X, Zhang J. The systematic effects of chitosan on fibroblasts derived from hypertrophic scars and keloids. Indian J Dermatol Venereol Leprol. 2012;78(4):520.
Bettinger DA, Yager DR, Diegelmann RF, Cohen IK. The effect of TGF-beta on keloid fibroblast proliferation and collagen synthesis. Plast Reconstr Surg. 1996;98(5):827–33.
Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev. 2004;56(5):581–7.
Funding
This work was supported financially by the National Research Foundation of Korea (NRF-2019R1A4A1024116, NRF-2019R1A2C2085962, and NRF-2018M3A9E2024583).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Park, J., Kim, YC. Topical delivery of 5-fluorouracil-loaded carboxymethyl chitosan nanoparticles using microneedles for keloid treatment. Drug Deliv. and Transl. Res. 11, 205–213 (2021). https://doi.org/10.1007/s13346-020-00781-w
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13346-020-00781-w